This session will go through the main features of the call with the main objective of providing answers to any questions or doubts from researchers considering the submission of projects to I2D2.
The purpose of I2D2 program is to accelerate the process whereby new disruptive therapeutic mechanisms reach patients, by using industrial standards to evaluate the mechanisms at the incubation stage for their potential for clinical application. Although the call will remain open, the first evaluation of Expressions of Interest will be made with those submissions received until September 30th, 2017.
►Please confirm attendance at the following link: https://www.eventbrite.com/o/15117691221
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del...
Palobiofarma S.L. is pleased to announce the “last patient last visi...
Biotechnology portal in Spain
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Biotech-Spain.com - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory